FDA approves Roche's Tecentriq for adjuvant stage III dMMR colon cancer

Roche has secured FDA approval for Tecentriq (atezolizumab) in combination with a fluoropyrimidine and oxaliplatin as adjuvant treatment for stage III deficient DNA mismatch repair (dMMR) colon cancer. The decision, announced on 9 October 2026, marks the twelfth US indication for the PD-L1 inhibitor and the first time an immunotherapy-based regimen has been cleared in the post-surgery colon cancer setting.

The approval applies to both the intravenous formulation, Tecentriq, and the subcutaneous co-formulation, Tecentriq Hybreza, making it the only PD-(L)1 therapy currently available in both delivery formats in the United States.

The ATOMIC data

The regulatory decision rests on the phase III ATOMIC trial, a 712-patient, randomised, open-label study sponsored by the US National Cancer Institute and led by the Alliance for Clinical Trials in Oncology. Results were published in the New England Journal of Medicine ahead of the approval.

Patients were randomised to receive either modified FOLFOX6 chemotherapy plus Tecentriq for six months, followed by Tecentriq monotherapy for a further six months, or mFOLFOX6 alone for six months. The primary endpoint was disease-free survival. At 36 months, DFS was 86% in the combination arm versus 76% in the chemotherapy-alone arm, translating to a 50% reduction in the risk of disease recurrence or death. The safety profile was reported as consistent with prior experience of both agents.

Frank Sinicrope, professor of oncology at the Mayo Clinic and US principal investigator for the trial, described the result as "practice-changing", noting that adjuvant treatment for stage III colon cancer had not previously been stratified by mismatch repair status. "By reducing the risk of disease recurrence or death by 50%, atezolizumab plus chemotherapy is a practice-changing regimen that can improve clinical outcomes of this group of patients," he said.

Market and competitive context

The dMMR or microsatellite instability-high (MSI-H) subtype accounts for roughly 15% of all colon cancer cases, according to published literature cited by Roche. Stage III disease as a whole represents nearly a quarter of all colon cancer diagnoses, and approximately 30% of stage III patients relapse within five years despite surgery and standard chemotherapy. That leaves a substantial addressable population for whom adjuvant immunotherapy has until now been unavailable.

Checkpoint inhibitors have already reshaped the metastatic colorectal cancer landscape, with pembrolizumab (Merck's Keytruda) approved for MSI-H/dMMR colorectal cancer in earlier lines and in the metastatic setting. The ATOMIC approval extends the immunotherapy frontier into the curative-intent adjuvant context, where the competitive field is currently unoccupied. Investigators and payers will scrutinise longer-term overall survival data as it matures, since the 36-month DFS readout, while compelling, does not yet confirm an OS benefit.

Roche has confirmed it is pursuing further regulatory submissions, including with the European Medicines Agency. An EMA decision would extend access to a large European patient population; colorectal cancer is among the leading causes of cancer-related death across the EU. Investors will watch for a timeline on the EMA filing and for any indication of whether Roche intends to pursue label expansion into stage II dMMR disease, where recurrence risk and immunotherapy sensitivity raise similar biological questions.